Aspen Capital Management’s AbbVie ABBV Stock Holding History

Aspen Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$315K	Buy	1,251 +2	+0.2%	+$430	0.07%	66
2026 Q1	$272K	Hold	1,249	–	–	0.07%	64
2025 Q4	$285K	Hold	1,249	–	–	0.07%	61
2025 Q3	$289K	Hold	1,249	–	–	0.07%	57
2025 Q2	$232K	Hold	1,249	–	–	0.07%	66
2025 Q1	$262K	Buy	+1,249	New	+$243K	0.08%	52

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Aspen Capital Management's ABBV Position: Q2 2026 in Review

Aspen Capital Management increased its AbbVie (ABBV) stake by 0.16% in Q2 2026, buying an estimated $430 and bringing the position to 1,251 shares worth $315K. The position accounts for 0.07% of the portfolio, ranked #66.

Aspen Capital Management first reported a position in ABBV in Q1 2025 and has held it in 6 quarters since. 4,192 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Aspen Capital Management held 1,251 shares of AbbVie worth $315K as of Q2 2026.
Aspen Capital Management bought 2 AbbVie shares in Q2 2026, an estimated $430.
AbbVie made up 0.07% of Aspen Capital Management's portfolio in Q2 2026, its #66 holding.
Aspen Capital Management first reported a position in AbbVie in Q1 2025 and has held it in 6 quarters since.
4,192 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Aspen Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.